← Ticker index
BBIO
Ticker
BBIO
Congressional Trades
23
by 1 members
Ticker disclosure brief
Congressional disclosure records for BBIO
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Gilbert Cisneros
BUY · 2026-05-11
Largest range
$1K – $15K
Gilbert Cisneros
Longest observed gap
38d
Gilbert Cisneros
Highest 30d vs SPY
60.8%
Gilbert Cisneros
Purchase rows
23
100%
Sale rows
0
0%
Disclosed midpoint
$184K
range estimate
Unique Traders
1
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats23 · 100%
Republicans0 · 0%
Lobbying filings
all →- 2026-07-09$60KBRIDGEBIO PHARMAIssues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
- 2026-04-20$420KBRIDGEBIO PHARMA INC.H.R.7148 - Consolidated Appropriations Act, 2026 Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Orphan drug policies General issues and provisions related to PBM Reform
- 2026-04-17$60KBRIDGEBIO PHARMAIssues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
- 2026-01-20$270KBRIDGEBIO PHARMA INC.Give Kids a Chance Act of 2025 - H.R. 1262; S 932 General issues and provisions related to PBM Reform ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies
- 2026-01-16$60KBRIDGEBIO PHARMAIssues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
- 2025-10-20$270KBRIDGEBIO PHARMA INC.Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Camerons Law - H.R. 1414 Tax Provisions in H.R. 1 - One Big Beautiful Bill Act - R&D tax credit, bonus depreciation, interest deduction Provisions related to PBM Reform in H.R. 1 - One Big Beautiful Bill Act PBM Reform Act - H.R. 4317 ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies Scientific EXPERT Act of 2025 - H.R. 1532; S. 822
- 2025-10-20$60KBRIDGEBIO PHARMAIssues related to pharmaceutical manufacturing, drug pricing, and orphan drugs.
- 2025-10-11$20KBRIDGEBIO PHARMAPBM Policy Reform. Prior authorization. Utilization management.
- 2025-07-30$20KBRIDGEBIO PHARMAPBM Policy Reform. Prior authorization. Utilization management.
- 2025-07-21$20KBRIDGEBIO PHARMAIssues related to pharmaceutical manufacturing, drug pricing, and orphan drugs.
Loading trade analytics…
All Disclosed Trades
Page 1 · 23 of 23 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2026-05-11 | DGilbert Cisneros | BUY | $1K – $15K | 29d | receipt → |
| 2026-05-11 | DGilbert Cisneros | BUY | $1K – $15K | 28d | receipt → |
| 2026-04-29 | DGilbert Cisneros | BUY | $1K – $15K | 12d | receipt → |
| 2026-04-29 | DGilbert Cisneros | BUY | $1K – $15K | 12d | receipt → |
| 2026-04-29 | DGilbert Cisneros | BUY | $1K – $15K | 9d | receipt → |
| 2026-03-18 | DGilbert Cisneros | BUY | $1K – $15K | 21d | receipt → |
| 2026-03-19 | DGilbert Cisneros | BUY | $1K – $15K | 20d | receipt → |
| 2026-03-19 | DGilbert Cisneros | BUY | $1K – $15K | 20d | receipt → |
| 2026-03-18 | DGilbert Cisneros | BUY | $1K – $15K | 21d | receipt → |
| 2026-03-03 | DGilbert Cisneros | BUY | $1K – $15K | 36d | receipt → |
| 2026-03-03 | DGilbert Cisneros | BUY | $1K – $15K | 36d | receipt → |
| 2026-03-18 | DGilbert Cisneros | BUY | $1K – $15K | 20d | receipt → |
| 2026-03-03 | DGilbert Cisneros | BUY | $1K – $15K | 35d | receipt → |
| 2026-03-03 | DGilbert Cisneros | BUY | $1K – $15K | 35d | receipt → |
| 2026-03-18 | DGilbert Cisneros | BUY | $1K – $15K | 20d | receipt → |
| 2026-03-19 | DGilbert Cisneros | BUY | $1K – $15K | 19d | receipt → |
| 2026-03-19 | DGilbert Cisneros | BUY | $1K – $15K | 19d | receipt → |
| 2025-09-22 | DGilbert Cisneros | BUY | $1K – $15K | 21d | receipt → |
| 2025-09-22 | DGilbert Cisneros | BUY | $1K – $15K | 18d | receipt → |
| 2025-09-22 | DGilbert Cisneros | BUY | $1K – $15K | 18d | receipt → |
| 2025-08-08 | DGilbert Cisneros | BUY | $1K – $15K | 38d | receipt → |
| 2025-08-08 | DGilbert Cisneros | BUY | $1K – $15K | 35d | receipt → |
| 2025-08-08 | DGilbert Cisneros | BUY | $1K – $15K | 35d | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.